Singapore, Sept. 18 -- IASO Biotechnology has received US Food and Drug Administration clearance for the Investigational New Drug application of IASO208, its CD20-targeted in vivo CAR-T therapy.

IASO208 is the first China-originated lentiviral vector-based in vivo CAR-T therapy to receive FDA IND clearance.

The candidate was developed using IASO Bio's proprietary InTelliCAR platform and is intended for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Following discussions with the FDA and supported by early clinical data generated in China, IASO208 is expected to move directly into a Phase Ib study in the United States.

Unlike conventional ex vivo CAR-T manufacturing, in vivo CAR-T approaches aim to generate engineere...